CA2252583A1 - Anticonvulsant pyridinyl benzamide derivatives - Google Patents
Anticonvulsant pyridinyl benzamide derivatives Download PDFInfo
- Publication number
- CA2252583A1 CA2252583A1 CA002252583A CA2252583A CA2252583A1 CA 2252583 A1 CA2252583 A1 CA 2252583A1 CA 002252583 A CA002252583 A CA 002252583A CA 2252583 A CA2252583 A CA 2252583A CA 2252583 A1 CA2252583 A1 CA 2252583A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compound
- compounds
- anticonvulsant
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A series of pyridinyl tri-substituted benzamide derivatives of general structure (I) wherein the symbols R1, R2, X and n are described in detail in the specification, are useful as anticonvulsants agents.
Description
CA 022~2~83 1998-10-23 WO 97/43261 PCTtUS97105960 Back~round of the Invention The invention pertains to novel pyridinyl benzamide derivatives having drug and bio-affecting properties and to their preparation, 5 pharmaceutical formulations and use. In particular, the invention concerns tri-substituted benzamides having a pyridine ring, with and without an alkyl linker, attached to the amide nitrogen. These compounds possess potent anticonvulsant properties that should make them useful in treating certain medical disorders.
The anticonvulsant drugs currently available in the United States have several shortcomings as therapeutic agents. About one of every three patients does not obtain significant relief from seizures and a number of side-effects accompany the therapeutic effects obtained. An underlying reason for the high incidence of side-effects is that most current 15 anticonvulsant agents possess low therapeutic ratios. For this reason, new anticonvulsants, which may possess greater selectivity and less toxicity in a clinical population, are needed.
A large number of various benzamide derivatives are known and the use of many of them as medicinals has been disclosed.
A number of amino-substituted benzamides have been disclosed as anticonvulsant agents. In general, these disclosed compounds have structural formula 1, wherein Z is a substituted phenyl or phenylalkyl moiety.
o H2N~NH-Z
For example, Robertson claims anticonvulsants, 2, in U.S. 4,684,748;
CA 022~2~83 1998-10-23 Me ~ Me H2N~ NH~
Me Me and in U.S. 4,981,866, Beedle and Robertson claim the use of various mono-substituted benzamide derivatives, 3. as anticonvulsants.
~ Me R1~ NH~
In formula 3, R1 can also be hydroxy, alkoxy and alkyl in addition to being substituted amino.
While a number of pyridinyl benzamide derivatives are known, they 10 are not tri-substituted benzamides and have not been particularly disclosed for use as anticonvulsant agents. These known pyridinyl benzamide compounds conform to the general structural formula _. In _, R1 can be hydrogen, halogen, alkyl, alkoxy, amino and nitro; R2 is generally amino;
o R1~ NH- A--and A is a chemical bond or an alkyl linking group.
As an example, Gadekar in U.S. 3,252,986 discloses a series of tranquilizers-muscle relaxants including compounds of formula 5.
CA 022~2~83 1998-10-23 o Cl~ NH-A- pyridine Similarly, Wright and Tomcufcik describe a series of pyridinyl benzamides of formula 6 disclosed as cardioprotective agents and 5 inhibitors of thromboxane synthetase. In 6, R is hydrogen, alkyl, o R[~NH- CnH
alkoxy, or nitro; and n is 2 to 5.
Kruger, et al. in U.S. 4,093,734 disclose a subset of pyridinyl 10 benzamides of formula 7 described as being useful anxiolytics, anticonvulsants, antiemetics, and antiulceragenics.
R2_~C- NH--(CH2)n--pyridyl In 7, R1 is hydrogen or halogen and R2 is methyl, halogen or nitro.
Of less significance are disclosures of metaclopramide-type benzamide derivatives having antiemetic and gastroprokinetic properties.
Monkovic, et al., are typical in disclosing a series of antiemetic tri-substituted benzamides, 8, in which CA 022~2~83 1998-10-23 R5 o R4~ NHR
R1 is a basic moiety such as -(CH2)n-NR7R8 or{~N-R7 .
These foregoing references do not teach or suggest the specific 5 novel pyridinyl tri-substituted benzamide derivatives of the present invention nor the anticonvulsant use of these compounds.
Summary and Detailed Description of the Invention In its broadest aspect, the present invention is concerned with specific tri-substituted pyridinylbenzamide derivatives having useful 10 anticonvulsant properties. In this regard, the invention encompasses novel compounds of Formula 1, their pharmaceutical formulations and their use as anticonvulsant agents.
In Formula 1, ~ NH- (CH2)n~
R1 is selected from hydrogen, lower acyl and lower alkyl;
R2 lower alkyl;
X is halogen; and n is zero or an integer from 1 to 4.
CA 022~2~83 1998-10-23 The term "lower" as used for lower acyl and lower alkyl refers to the number of carbon atoms contained in the functional group and should be understood to comprise from one to four carbon atoms; e.g., formyl to butanoyl and methyl to butyl. "Halogen" refers to fluorine, chlorine, bromine 5 and iodine. As can be seen from the definition of n, the pyridine moiety can be directly bonded to the amide nitrogen or can be linked by an alkanediyl group of from one to four methylene units.
Preferred cl~sses of compounds of Formula I are those wherein R1 is hydrogen, R2 is methyl, X is chloro and n is 1.
Additionally, compounds of Formula I also encompass all pharmaceutically acceptable acid addition salts and/or solvates, particularly hydrates, thereof. The present invention also encompasses any and all isomers of compounds of Formula 1.
The pharmaceutically acceptable acid addition salts of the invention 15 are those in which the counter-ion does not contribute significantly to the toxicity or pharmacological activity of the salt and, as such, they are the pharmacological equivalents of the bases of Formula 1. They are generally preferred for medical usage. In some instances, they have physical properties which make them more desirable for pharmaceutical formulation 20 such as solubility, lack of hygroscopicity, compressibility with respect to tablet formation and compatibility with other ingredients with which the substance may be used for pharmaceutical purposes. The salts are routinely made by admixture of a Formula I base with the selected acid preferably by contact in solution employing an excess of commonly used 25 inert solvents such as water, ether, benzene, methanol, ethanol, ethyl acetate and acetonitrile. They may also be made by metathesis or treatment with an ion exchange resin under conditions in which the anion of one salt of the substance of the Formula I is replaced by another anion under conditions which allow for separation of the desired species such as 30 by precipitation from solution or extraction into a solvent, or elution from or retention on an ion exchange resin. Pharmaceutically acceptable acids for the purposes of salt formation of the substances of Formula I include sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, citric, acetic, benzoic, cinnamic, mandelic, phosphoric, nitric, mucic, isethionic, palmitic, 35 heptanoic and others.
CA 022~2~83 1998-10-23 The compounds of Formula I can be prepared by means of the process shown in Scheme 1. R1, R2, X and n are as previously described.
Scheme 1 o o X~OH 1. CDI _ X~N--(CH2)n~
R1NH~oR2 2.H2N--(cH2)n--~I R1NH~oR2 N
(111) (Il) ~I) In a straighfforward manner, a starting tri-substituted benzoic acid (Ill) is coupled with an appropriate starting pyridinyl amine (Il) by using 1,1-carbonyldiimidazole (CDI) or another peptide coupling agent (e.g. 1,3-dicyclohexylcarbodiimide, or the like) in a suitable reaction solvent with heating. In practice, the use of CDI in refluxing tetrahydrofuran (THF) is preferred for production of products (I). It would be understood that certain variations in the process could be made affording similar Formula I
compounds. Similarly, other variations in reagents, solvents, and reaction conditions for the Scheme I process would be known to one skilled in the art. The various starting materials of Formulas ll and lll are, in general, commercially available. They may also be synthesized using procedures readily available in the chemical literature.
The above processes may be adapted to variation in order to produce other compounds embraced by this invention but not specifically disclosed. Variations of the methods to produce the same compounds in somewhat different fashion will also be evident to one skilled in the art. To provide greater descriptive detail, representative synthetic examples are set out in the "Description of Specific Embodiments" section hereinbelow.
The compounds of Formula I are anticonvulsant agents. Their anticonvulsant properties were determined by pharmacologic testing, utilizing two standard animal models of epilepsy: the pentylenetetrazole (PTZ)-induced seizure procedure and the maximal electroshock test (MES).
General descriptions of such testing can be found in J.F. Reinhard and J.F.
Reinhard, Jr., "Experimental Evaluation of Anticonvulsants," in CA 022~2~83 1998-10-23 Anticonvulsants. J.A. Vida, Ed., Academic Press, New York, New York, 1 977.
The anticonvulsant tri-substituted benzamide pyridine derivatives of Formula I may be administered by various routes including the oral, rectal, 5 transdermal, subcutaneous, intravenous, intramuscular, or intranasal routes, being usually employed in the form of a pharmaceutical composition. The invention includes a pharmaceutical composition comprising from about 1% to about 95% by weight of a compound of Formula 1, or a pharmaceutically acceptable acid addition salt thereof, 10 associated with a pharmaceutically acceptable carrier.
In making the compositions of the present invention, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a 15 solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient. Thus, the composition can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing for example up to 10% by weight of the active 20 compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
Some examples of suitable carriers and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline 25 cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl- and propylhydroxybenzoates, talc, magnesium stearate and mineral oil. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents. The compositions of the invention may be 30 formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.
The compositions are preferably formulated in a unit dosage form, each dosage containing from about 2.5 to 500 mg, more usually 25 to 300 mg, of the active ingredient. The term "unit dosage form" refers to physically CA 022~2~83 1998-10-23 discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier.
The active compounds are effective over a wide dosage range. For example, dosages per day will normally fall within the range of about 0.5 to 300 mg/kg of body weight. In the treatment of adult humans, the range of about 1 to 50 mg/kg, in single or divided doses, is preferred. However, it will be understood that the amount of the compound actually administered will 10 be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, the chosen route of administration, the age, weight, and response of the individual patient, and the severity of the patient's sy, I ,~t~" ,s.
For treating epilepsy, a compound of Formula I may be employed as a daily dosage in the range of about 50 mg to about 2000 mg, usually in 1 to 4 divided dosages, for an average adult human. A unit dos~ge would contain about 2.5 mg to about 500 mg of the active ingredient.
In general, compounds of Formula I may be used in treating epilepsy 20 in mammals including humans in a manner similar to that used for phenytoin. Medical aspects of the treating of epilepsy are described in greater detail by Rail and Schleifer in Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed.; Goodman Gilman, A.; Rall, T.W.; Nies, A.S.; Taylor, P., Eds.; Pergamon Press: New York, 1990; pp.
25 436-462.
Description of Specific Embodiments The compounds which constitute this invention, their methods of preparation and their biologic actions will appear more fully from consideration of the following examples, which are given for the purpose of 30 illustration only and are not to be construed as limiting the invention in sphere or scope. In the following examples, used to illustrate the foregoing synthetic processes, temperatures are expressed in degrees Celsius and melting points are uncorrected. The nuclear magnetic resonances (NMR) CA 022~2~83 1998-10-23 are spectral characteristics refer to Chemical shifts (~) expressed as parts per million (ppm) versus tetramethylsilane (TMS) as reference standard.
The relative area reported for the various shifts in the 1 H NMR spectral data corresponds to the number of hydrogen atoms of a particular functional type 5 in the molecule. The nature of the shifts as to multiplicity is reported as a broad singlet (bs), singlet (s), multiplet (m) or doublet (d). Abbreviations employed are DMSO-d6 (deuterodimethylsulfoxide), CDCI3 (deuterochloroform) and are otherwise conventional. The infrared (IR) spectral descriptions include only absorption wave numbers (cm~1) having 10 functional group identification value. The IR determinations were employed using potassium bromide (KBr) as diluent. The elemental analyses are reported as percent by weight.
The following examples describe in detail the preparation of compounds of Formula 1. It will be apparent to those skilled in the art that 15 modifications, both of materials and methods, will allow preparation of other compounds disclosed herein. From the foregoing description and the following examples it is believed that one skilled in the art is able to use theinvention to the fullest extent.
Compounds of Formula I
Example 1 General Method: 4-Amino-5-chloro-2-methoxy-N-(3-pyridinylmethyl)benzamide To a solution of 4-amino-5-chloro-2-methoxybenzoic acid (1.0 eq) in THF was added CDI (1.0 eq) and this was heated to reflux under nitrogen 25 for 20 min. To this was added the 3-pyridinylmethylamine (1.0 eq) in THF
(10 ml) and the reaction was heated to reflux overnight. The solvent was removed in vacuo and the resultant solid was purified by recrystallization from acetonitrile. The free base was characterized as follows: m.p. 158-161~ C; 1H NMR (300 MHz, CDCI3) ~ 8.56 (s,1H), 8.48 (d, J=3 Hz,1H), 8.10 30 (s,1 H), 8.02 (bd, J=6 Hz,1 H), 7.66 (m,1 H), 7.23 (m,1 H), 6.26 (s,1 H), 4.62 (d, J=6 Hz, 2H), 4.43 (bs, 2H), 3.83 (s, 3H); 13C NMR (75 MHz, CDCI3) ~
164.7, 157.5,148.9,148.6, 146.9,135.5,134.7, 133.3,123.5,111.9, 111.7, CA 022~2~83 1998-10-23 97.7, 56.1, 41.1; IR (KBr) 3400, 1650, 1545, 1270, 750 cm-1; MS (DCI) m/e 583 (MH+M), 292 (MH); Analysis calc'd for C14H14N3O2CI1: C, 57.64; H, 4.84; N, 14.40;found: C, 57.39; H, 4.77; N, 14.31.
The hydrochloride salt was prepared by adding ethanolic HCI to an 5 acetonitrile solution of the free base. Characterization of the HCI salt: m.p.> 220~ C; 1 H NMR (300 MHz, DMSO-d6) ~ 8.82 (s, 2H), 8.80 (s, 1 H), 8.73 (t, J=6 Hz, 1 H), 8.02 (dd, J=6, 9 Hz, 1 H), 7.65 (s, 1 H), 6.51 (s, 1 H), 4.63 (d, J=6 Hz, 2H), 3.84 (s, 3H); 13C NMR (75 MHz, DMSO-d6) ~164.311, 157.69, 148.91, 144.66, 140.31,139.94, 131.65,126.88, 109.52,108.85, 97.33, 55.86; IR (KBr) 3200, 2500, 1640, 1555, 1255, 775 cm-1; MS (DCI) m/e 292 (MH); Analysis calc'd for C14H1sN3O2CI2: C, 51.24; H, 4.61; N, 12.80;
found: C, 51.30; H, 4.59; N, 12.89.
Example 2 4-Amino-5-chloro-2-methoxy-N-(2-pyridinylmethyl)benzamide Prepared analogously to the general procedure using 2-aminomethylpyridine. m.p. 161-163~ C; 1H NMR (300 MHz, CDCI3) ~ 8.68 (bs, 1H), 8.51 (m, 1H), 8.08 (s, 1H), 7.60 (m, 1H), 7.29 (d, J=6 Hz, 1H), 7.14 (m, 1H), 6.26 (s, 1H), 4.72 (d, J=3 Hz, 2H), 4.83 (bs, 2H), 3.84 (s, 3H); 13C
NMR (75 MHz, CDCI3) ~164.6, 157.7, 157.6, 149.0, 146.9, 136.7, 133.0, 122.1, 122.0, 1 12.2, 1 1 1 .4, 97.8, 56.1, 45.2; IR (KBr) 3500, 1650, 1540, 1250, 765 cm-1; MS (DCI) m/e 292 (MH); Analysis calc'd for C14H14N3O2C11: C, 57.64; H, 4.84; N, 14.40; found: C, 57.75; H, 4.84; N, 14.40.
Example 3 4-Amino-5-chloro-2-methoxy-N-(4-pyridinylmethyl)benzamide Free base prepared analogously to the general procedure using 4-aminomethylpyridine. m.p. 160-162~ C; 1 H NMR (300 MHz, CDCI3) ~ 8.50 (bs, 2H), 8.08 (s, 2H), 7.20 (d, J=6 Hz, 2H), 6.28 (s, 1H), 4.61 (d, J=6 Hz, 2H), 4.45 (bs, 2H), 3.84 (s, 3H); 13C NMR (75 MHz, CDCI3) ~164.9, 157.6, 149.8, 148.3, 147.2, 133.3, 122.1, 111.6, 97.7, 56.2, 42.5; IR (KBr) 3450, CA 022~2s83 l998-l0-23 W 097/43261 1 1 PCT~US97/05960 1640, 1540, 1250, 830 cm-1; MS (DCI) m/e 583 (MH+M), 292 (MH); Analysis calc'd for C14H14N3O2CI1: C, 57.64; H, 4.84; N,14.40; found: C, 57.66; H, 4.75; N, 14.51.
Measurement of Anticonvulsant Properties Example 4 The Maximum Electroshock (MES) Procedure In the MES procedure a tonic seizure was produced in female C57BI/6 mice (17-26 g) by the delivery of a 50 milliamps current through corneal electrodes for 0.2 sec. Before testing, animals were allowed food and water ad libitum. Compounds were injected i.p. (vol = 0.1 mU20 g) 30 min. before the MES. Reference compounds (phenytoin, carbamazepine, phenobarbital, and valproic acid) were tested at the time of peak activity and at the dose range reported in the literature. Seven mice were used per group. In this test anticonvulsive activity was indicated by the abolition of the hindlimb tonic extension. The median effective dose (EDso) was obtained for each compound.
Example 5 The Pentylenetetrazole (PZT)-lnduced Seizure Procedure In the PTZ procedure female C57BI/6 mice (17-26 g) were injected i.p. (vol = 0.1 mU20 g) with test compound or vehicle 30 min. before i.p.
administration of 75 mg/kg pentylenetetrazol. Multiple doses of reference compounds (ethosuximide, trimethadione, and pentobarbital) were tested at the time of peak activity and at the dose range reported in the literature. Ten mice were used per group. After injection, mice were placed in individual observation cages and monitored for one hour. During the first 30 minutes following PTZ injection, seizure activity was recorded by measuring: the latency to the onset of pre-convulsive activity, the latency to the onset of thefirst clonic seizure longer than five seconds, the latency to the onset of the first intense-generalized clonic/tonic seizure, and the length of survival.
During the second 30 min. period, only time of death was recorded. Those CA 022~2~83 1998-10-23 compounds that produced a significant delay in the onset of seizure activity or delayed (or abolished) mortality when compared to that produced by vehicle were classified as anticonvulsants. Significant difference between animals treated with vehicle or test compound were determined using the 5 Student's t-test.
The anticonvulsant activity of some selected compounds of Formula I
is displayed in Table 2.
Table 2 Summar,v of Anticonvulsive Activity of Some Selected Formula I Benzamides PTZ Anticonvulsive Resu ts*
Ex. # MES** Surv Results Pre First Time IGS Surv + ++ ++++ ++++ +++ ++++
The anticonvulsant drugs currently available in the United States have several shortcomings as therapeutic agents. About one of every three patients does not obtain significant relief from seizures and a number of side-effects accompany the therapeutic effects obtained. An underlying reason for the high incidence of side-effects is that most current 15 anticonvulsant agents possess low therapeutic ratios. For this reason, new anticonvulsants, which may possess greater selectivity and less toxicity in a clinical population, are needed.
A large number of various benzamide derivatives are known and the use of many of them as medicinals has been disclosed.
A number of amino-substituted benzamides have been disclosed as anticonvulsant agents. In general, these disclosed compounds have structural formula 1, wherein Z is a substituted phenyl or phenylalkyl moiety.
o H2N~NH-Z
For example, Robertson claims anticonvulsants, 2, in U.S. 4,684,748;
CA 022~2~83 1998-10-23 Me ~ Me H2N~ NH~
Me Me and in U.S. 4,981,866, Beedle and Robertson claim the use of various mono-substituted benzamide derivatives, 3. as anticonvulsants.
~ Me R1~ NH~
In formula 3, R1 can also be hydroxy, alkoxy and alkyl in addition to being substituted amino.
While a number of pyridinyl benzamide derivatives are known, they 10 are not tri-substituted benzamides and have not been particularly disclosed for use as anticonvulsant agents. These known pyridinyl benzamide compounds conform to the general structural formula _. In _, R1 can be hydrogen, halogen, alkyl, alkoxy, amino and nitro; R2 is generally amino;
o R1~ NH- A--and A is a chemical bond or an alkyl linking group.
As an example, Gadekar in U.S. 3,252,986 discloses a series of tranquilizers-muscle relaxants including compounds of formula 5.
CA 022~2~83 1998-10-23 o Cl~ NH-A- pyridine Similarly, Wright and Tomcufcik describe a series of pyridinyl benzamides of formula 6 disclosed as cardioprotective agents and 5 inhibitors of thromboxane synthetase. In 6, R is hydrogen, alkyl, o R[~NH- CnH
alkoxy, or nitro; and n is 2 to 5.
Kruger, et al. in U.S. 4,093,734 disclose a subset of pyridinyl 10 benzamides of formula 7 described as being useful anxiolytics, anticonvulsants, antiemetics, and antiulceragenics.
R2_~C- NH--(CH2)n--pyridyl In 7, R1 is hydrogen or halogen and R2 is methyl, halogen or nitro.
Of less significance are disclosures of metaclopramide-type benzamide derivatives having antiemetic and gastroprokinetic properties.
Monkovic, et al., are typical in disclosing a series of antiemetic tri-substituted benzamides, 8, in which CA 022~2~83 1998-10-23 R5 o R4~ NHR
R1 is a basic moiety such as -(CH2)n-NR7R8 or{~N-R7 .
These foregoing references do not teach or suggest the specific 5 novel pyridinyl tri-substituted benzamide derivatives of the present invention nor the anticonvulsant use of these compounds.
Summary and Detailed Description of the Invention In its broadest aspect, the present invention is concerned with specific tri-substituted pyridinylbenzamide derivatives having useful 10 anticonvulsant properties. In this regard, the invention encompasses novel compounds of Formula 1, their pharmaceutical formulations and their use as anticonvulsant agents.
In Formula 1, ~ NH- (CH2)n~
R1 is selected from hydrogen, lower acyl and lower alkyl;
R2 lower alkyl;
X is halogen; and n is zero or an integer from 1 to 4.
CA 022~2~83 1998-10-23 The term "lower" as used for lower acyl and lower alkyl refers to the number of carbon atoms contained in the functional group and should be understood to comprise from one to four carbon atoms; e.g., formyl to butanoyl and methyl to butyl. "Halogen" refers to fluorine, chlorine, bromine 5 and iodine. As can be seen from the definition of n, the pyridine moiety can be directly bonded to the amide nitrogen or can be linked by an alkanediyl group of from one to four methylene units.
Preferred cl~sses of compounds of Formula I are those wherein R1 is hydrogen, R2 is methyl, X is chloro and n is 1.
Additionally, compounds of Formula I also encompass all pharmaceutically acceptable acid addition salts and/or solvates, particularly hydrates, thereof. The present invention also encompasses any and all isomers of compounds of Formula 1.
The pharmaceutically acceptable acid addition salts of the invention 15 are those in which the counter-ion does not contribute significantly to the toxicity or pharmacological activity of the salt and, as such, they are the pharmacological equivalents of the bases of Formula 1. They are generally preferred for medical usage. In some instances, they have physical properties which make them more desirable for pharmaceutical formulation 20 such as solubility, lack of hygroscopicity, compressibility with respect to tablet formation and compatibility with other ingredients with which the substance may be used for pharmaceutical purposes. The salts are routinely made by admixture of a Formula I base with the selected acid preferably by contact in solution employing an excess of commonly used 25 inert solvents such as water, ether, benzene, methanol, ethanol, ethyl acetate and acetonitrile. They may also be made by metathesis or treatment with an ion exchange resin under conditions in which the anion of one salt of the substance of the Formula I is replaced by another anion under conditions which allow for separation of the desired species such as 30 by precipitation from solution or extraction into a solvent, or elution from or retention on an ion exchange resin. Pharmaceutically acceptable acids for the purposes of salt formation of the substances of Formula I include sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, citric, acetic, benzoic, cinnamic, mandelic, phosphoric, nitric, mucic, isethionic, palmitic, 35 heptanoic and others.
CA 022~2~83 1998-10-23 The compounds of Formula I can be prepared by means of the process shown in Scheme 1. R1, R2, X and n are as previously described.
Scheme 1 o o X~OH 1. CDI _ X~N--(CH2)n~
R1NH~oR2 2.H2N--(cH2)n--~I R1NH~oR2 N
(111) (Il) ~I) In a straighfforward manner, a starting tri-substituted benzoic acid (Ill) is coupled with an appropriate starting pyridinyl amine (Il) by using 1,1-carbonyldiimidazole (CDI) or another peptide coupling agent (e.g. 1,3-dicyclohexylcarbodiimide, or the like) in a suitable reaction solvent with heating. In practice, the use of CDI in refluxing tetrahydrofuran (THF) is preferred for production of products (I). It would be understood that certain variations in the process could be made affording similar Formula I
compounds. Similarly, other variations in reagents, solvents, and reaction conditions for the Scheme I process would be known to one skilled in the art. The various starting materials of Formulas ll and lll are, in general, commercially available. They may also be synthesized using procedures readily available in the chemical literature.
The above processes may be adapted to variation in order to produce other compounds embraced by this invention but not specifically disclosed. Variations of the methods to produce the same compounds in somewhat different fashion will also be evident to one skilled in the art. To provide greater descriptive detail, representative synthetic examples are set out in the "Description of Specific Embodiments" section hereinbelow.
The compounds of Formula I are anticonvulsant agents. Their anticonvulsant properties were determined by pharmacologic testing, utilizing two standard animal models of epilepsy: the pentylenetetrazole (PTZ)-induced seizure procedure and the maximal electroshock test (MES).
General descriptions of such testing can be found in J.F. Reinhard and J.F.
Reinhard, Jr., "Experimental Evaluation of Anticonvulsants," in CA 022~2~83 1998-10-23 Anticonvulsants. J.A. Vida, Ed., Academic Press, New York, New York, 1 977.
The anticonvulsant tri-substituted benzamide pyridine derivatives of Formula I may be administered by various routes including the oral, rectal, 5 transdermal, subcutaneous, intravenous, intramuscular, or intranasal routes, being usually employed in the form of a pharmaceutical composition. The invention includes a pharmaceutical composition comprising from about 1% to about 95% by weight of a compound of Formula 1, or a pharmaceutically acceptable acid addition salt thereof, 10 associated with a pharmaceutically acceptable carrier.
In making the compositions of the present invention, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a 15 solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient. Thus, the composition can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing for example up to 10% by weight of the active 20 compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
Some examples of suitable carriers and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline 25 cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl- and propylhydroxybenzoates, talc, magnesium stearate and mineral oil. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents. The compositions of the invention may be 30 formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.
The compositions are preferably formulated in a unit dosage form, each dosage containing from about 2.5 to 500 mg, more usually 25 to 300 mg, of the active ingredient. The term "unit dosage form" refers to physically CA 022~2~83 1998-10-23 discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier.
The active compounds are effective over a wide dosage range. For example, dosages per day will normally fall within the range of about 0.5 to 300 mg/kg of body weight. In the treatment of adult humans, the range of about 1 to 50 mg/kg, in single or divided doses, is preferred. However, it will be understood that the amount of the compound actually administered will 10 be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, the chosen route of administration, the age, weight, and response of the individual patient, and the severity of the patient's sy, I ,~t~" ,s.
For treating epilepsy, a compound of Formula I may be employed as a daily dosage in the range of about 50 mg to about 2000 mg, usually in 1 to 4 divided dosages, for an average adult human. A unit dos~ge would contain about 2.5 mg to about 500 mg of the active ingredient.
In general, compounds of Formula I may be used in treating epilepsy 20 in mammals including humans in a manner similar to that used for phenytoin. Medical aspects of the treating of epilepsy are described in greater detail by Rail and Schleifer in Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed.; Goodman Gilman, A.; Rall, T.W.; Nies, A.S.; Taylor, P., Eds.; Pergamon Press: New York, 1990; pp.
25 436-462.
Description of Specific Embodiments The compounds which constitute this invention, their methods of preparation and their biologic actions will appear more fully from consideration of the following examples, which are given for the purpose of 30 illustration only and are not to be construed as limiting the invention in sphere or scope. In the following examples, used to illustrate the foregoing synthetic processes, temperatures are expressed in degrees Celsius and melting points are uncorrected. The nuclear magnetic resonances (NMR) CA 022~2~83 1998-10-23 are spectral characteristics refer to Chemical shifts (~) expressed as parts per million (ppm) versus tetramethylsilane (TMS) as reference standard.
The relative area reported for the various shifts in the 1 H NMR spectral data corresponds to the number of hydrogen atoms of a particular functional type 5 in the molecule. The nature of the shifts as to multiplicity is reported as a broad singlet (bs), singlet (s), multiplet (m) or doublet (d). Abbreviations employed are DMSO-d6 (deuterodimethylsulfoxide), CDCI3 (deuterochloroform) and are otherwise conventional. The infrared (IR) spectral descriptions include only absorption wave numbers (cm~1) having 10 functional group identification value. The IR determinations were employed using potassium bromide (KBr) as diluent. The elemental analyses are reported as percent by weight.
The following examples describe in detail the preparation of compounds of Formula 1. It will be apparent to those skilled in the art that 15 modifications, both of materials and methods, will allow preparation of other compounds disclosed herein. From the foregoing description and the following examples it is believed that one skilled in the art is able to use theinvention to the fullest extent.
Compounds of Formula I
Example 1 General Method: 4-Amino-5-chloro-2-methoxy-N-(3-pyridinylmethyl)benzamide To a solution of 4-amino-5-chloro-2-methoxybenzoic acid (1.0 eq) in THF was added CDI (1.0 eq) and this was heated to reflux under nitrogen 25 for 20 min. To this was added the 3-pyridinylmethylamine (1.0 eq) in THF
(10 ml) and the reaction was heated to reflux overnight. The solvent was removed in vacuo and the resultant solid was purified by recrystallization from acetonitrile. The free base was characterized as follows: m.p. 158-161~ C; 1H NMR (300 MHz, CDCI3) ~ 8.56 (s,1H), 8.48 (d, J=3 Hz,1H), 8.10 30 (s,1 H), 8.02 (bd, J=6 Hz,1 H), 7.66 (m,1 H), 7.23 (m,1 H), 6.26 (s,1 H), 4.62 (d, J=6 Hz, 2H), 4.43 (bs, 2H), 3.83 (s, 3H); 13C NMR (75 MHz, CDCI3) ~
164.7, 157.5,148.9,148.6, 146.9,135.5,134.7, 133.3,123.5,111.9, 111.7, CA 022~2~83 1998-10-23 97.7, 56.1, 41.1; IR (KBr) 3400, 1650, 1545, 1270, 750 cm-1; MS (DCI) m/e 583 (MH+M), 292 (MH); Analysis calc'd for C14H14N3O2CI1: C, 57.64; H, 4.84; N, 14.40;found: C, 57.39; H, 4.77; N, 14.31.
The hydrochloride salt was prepared by adding ethanolic HCI to an 5 acetonitrile solution of the free base. Characterization of the HCI salt: m.p.> 220~ C; 1 H NMR (300 MHz, DMSO-d6) ~ 8.82 (s, 2H), 8.80 (s, 1 H), 8.73 (t, J=6 Hz, 1 H), 8.02 (dd, J=6, 9 Hz, 1 H), 7.65 (s, 1 H), 6.51 (s, 1 H), 4.63 (d, J=6 Hz, 2H), 3.84 (s, 3H); 13C NMR (75 MHz, DMSO-d6) ~164.311, 157.69, 148.91, 144.66, 140.31,139.94, 131.65,126.88, 109.52,108.85, 97.33, 55.86; IR (KBr) 3200, 2500, 1640, 1555, 1255, 775 cm-1; MS (DCI) m/e 292 (MH); Analysis calc'd for C14H1sN3O2CI2: C, 51.24; H, 4.61; N, 12.80;
found: C, 51.30; H, 4.59; N, 12.89.
Example 2 4-Amino-5-chloro-2-methoxy-N-(2-pyridinylmethyl)benzamide Prepared analogously to the general procedure using 2-aminomethylpyridine. m.p. 161-163~ C; 1H NMR (300 MHz, CDCI3) ~ 8.68 (bs, 1H), 8.51 (m, 1H), 8.08 (s, 1H), 7.60 (m, 1H), 7.29 (d, J=6 Hz, 1H), 7.14 (m, 1H), 6.26 (s, 1H), 4.72 (d, J=3 Hz, 2H), 4.83 (bs, 2H), 3.84 (s, 3H); 13C
NMR (75 MHz, CDCI3) ~164.6, 157.7, 157.6, 149.0, 146.9, 136.7, 133.0, 122.1, 122.0, 1 12.2, 1 1 1 .4, 97.8, 56.1, 45.2; IR (KBr) 3500, 1650, 1540, 1250, 765 cm-1; MS (DCI) m/e 292 (MH); Analysis calc'd for C14H14N3O2C11: C, 57.64; H, 4.84; N, 14.40; found: C, 57.75; H, 4.84; N, 14.40.
Example 3 4-Amino-5-chloro-2-methoxy-N-(4-pyridinylmethyl)benzamide Free base prepared analogously to the general procedure using 4-aminomethylpyridine. m.p. 160-162~ C; 1 H NMR (300 MHz, CDCI3) ~ 8.50 (bs, 2H), 8.08 (s, 2H), 7.20 (d, J=6 Hz, 2H), 6.28 (s, 1H), 4.61 (d, J=6 Hz, 2H), 4.45 (bs, 2H), 3.84 (s, 3H); 13C NMR (75 MHz, CDCI3) ~164.9, 157.6, 149.8, 148.3, 147.2, 133.3, 122.1, 111.6, 97.7, 56.2, 42.5; IR (KBr) 3450, CA 022~2s83 l998-l0-23 W 097/43261 1 1 PCT~US97/05960 1640, 1540, 1250, 830 cm-1; MS (DCI) m/e 583 (MH+M), 292 (MH); Analysis calc'd for C14H14N3O2CI1: C, 57.64; H, 4.84; N,14.40; found: C, 57.66; H, 4.75; N, 14.51.
Measurement of Anticonvulsant Properties Example 4 The Maximum Electroshock (MES) Procedure In the MES procedure a tonic seizure was produced in female C57BI/6 mice (17-26 g) by the delivery of a 50 milliamps current through corneal electrodes for 0.2 sec. Before testing, animals were allowed food and water ad libitum. Compounds were injected i.p. (vol = 0.1 mU20 g) 30 min. before the MES. Reference compounds (phenytoin, carbamazepine, phenobarbital, and valproic acid) were tested at the time of peak activity and at the dose range reported in the literature. Seven mice were used per group. In this test anticonvulsive activity was indicated by the abolition of the hindlimb tonic extension. The median effective dose (EDso) was obtained for each compound.
Example 5 The Pentylenetetrazole (PZT)-lnduced Seizure Procedure In the PTZ procedure female C57BI/6 mice (17-26 g) were injected i.p. (vol = 0.1 mU20 g) with test compound or vehicle 30 min. before i.p.
administration of 75 mg/kg pentylenetetrazol. Multiple doses of reference compounds (ethosuximide, trimethadione, and pentobarbital) were tested at the time of peak activity and at the dose range reported in the literature. Ten mice were used per group. After injection, mice were placed in individual observation cages and monitored for one hour. During the first 30 minutes following PTZ injection, seizure activity was recorded by measuring: the latency to the onset of pre-convulsive activity, the latency to the onset of thefirst clonic seizure longer than five seconds, the latency to the onset of the first intense-generalized clonic/tonic seizure, and the length of survival.
During the second 30 min. period, only time of death was recorded. Those CA 022~2~83 1998-10-23 compounds that produced a significant delay in the onset of seizure activity or delayed (or abolished) mortality when compared to that produced by vehicle were classified as anticonvulsants. Significant difference between animals treated with vehicle or test compound were determined using the 5 Student's t-test.
The anticonvulsant activity of some selected compounds of Formula I
is displayed in Table 2.
Table 2 Summar,v of Anticonvulsive Activity of Some Selected Formula I Benzamides PTZ Anticonvulsive Resu ts*
Ex. # MES** Surv Results Pre First Time IGS Surv + ++ ++++ ++++ +++ ++++
2 NT ++ ++++ +++ NT ++++
3 +++ ++ ++++ ++++ +++ ++++
*50 mg/kg i.p. For PTZ results: + = > 100% of controls;
++ = > 200% of controls; +++ = > 300% of controls;
++++ = > 400% of controls **For MES results: median effective dose (ED50): + = < 75 mg/kg;
++ = < 25 mg/kg; +++ = c 10 mg/kg Pre: latency to first twitch First: latency to first seizure Surv Time: duration of survival IGS: onset of intense, generalized seizures Surv: survival at one hour post-PTZ
MES: maximum electroshock NT: not tested
*50 mg/kg i.p. For PTZ results: + = > 100% of controls;
++ = > 200% of controls; +++ = > 300% of controls;
++++ = > 400% of controls **For MES results: median effective dose (ED50): + = < 75 mg/kg;
++ = < 25 mg/kg; +++ = c 10 mg/kg Pre: latency to first twitch First: latency to first seizure Surv Time: duration of survival IGS: onset of intense, generalized seizures Surv: survival at one hour post-PTZ
MES: maximum electroshock NT: not tested
Claims (10)
1. The compound of Formula I and its pharmaceutically acceptable salts and hydrates thereof, wherein R1 is selected from hydrogen, lower acyl, and lower alkyl;
R2 is lower alkyl;
X is halogen; and n is zero or an integer selected from 1 to 4.
R2 is lower alkyl;
X is halogen; and n is zero or an integer selected from 1 to 4.
2. The compound of Formula I wherein R1 is hydrogen.
3. The compound of Formula I wherein R2 is methyl.
4. The compound of Formula I wherein X is chloro.
5. The compound of Formula I wherein n is 1.
6. The compound of Formula I wherein R1 is hydrogen, R2 is methyl, and X is chloro.
7. The compound of Formula I wherein the pyridine ring is attached at its 3-position.
8. A compound of claim 6 wherein the pyridine ring is attached at its 3-position.
9. A method for eliciting an anticonvulsant effect in a mammal in need thereof by the administration of an effective amount of a claim 1 compound to a mammal in need thereof.
10. A pharmaceutical composition for eliciting an anticonvulsant effect, the composition being in unit dosage form suitable for systemic administration to a mammalian host comprising a pharmaceutical carrier and from about 1 to 500 mg of a compound of claim 1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1756596P | 1996-05-14 | 1996-05-14 | |
| US60/017,565 | 1996-05-14 | ||
| PCT/US1997/005960 WO1997043261A1 (en) | 1996-05-14 | 1997-04-10 | Anticonvulsant pyridinyl benzamide derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2252583A1 true CA2252583A1 (en) | 1997-11-20 |
Family
ID=21783299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002252583A Abandoned CA2252583A1 (en) | 1996-05-14 | 1997-04-10 | Anticonvulsant pyridinyl benzamide derivatives |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0912516A4 (en) |
| JP (1) | JP2000510146A (en) |
| AU (1) | AU710071B2 (en) |
| CA (1) | CA2252583A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES438120A1 (en) * | 1975-06-02 | 1977-02-01 | Gallardo Antonio Sa | Procedure for the preparation of aromatic amidas. (Machine-translation by Google Translate, not legally binding) |
| FI763021A (en) * | 1975-11-03 | 1977-05-04 | Thomae Gmbh Dr K | |
| US4684748A (en) * | 1985-07-26 | 1987-08-04 | Eli Lilly And Company | Anticonvulsant agents |
| US4642379A (en) * | 1985-08-30 | 1987-02-10 | Eli Lilly And Company | Intermediates for anticonvulsant agents |
| US4981866A (en) * | 1987-02-18 | 1991-01-01 | Eli Lilly And Company | Anticonvulsant agents |
-
1997
- 1997-04-10 CA CA002252583A patent/CA2252583A1/en not_active Abandoned
- 1997-04-10 EP EP97920305A patent/EP0912516A4/en not_active Withdrawn
- 1997-04-10 JP JP09540866A patent/JP2000510146A/en not_active Ceased
- 1997-04-10 AU AU24532/97A patent/AU710071B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP0912516A1 (en) | 1999-05-06 |
| AU710071B2 (en) | 1999-09-16 |
| JP2000510146A (en) | 2000-08-08 |
| AU2453297A (en) | 1997-12-05 |
| EP0912516A4 (en) | 2002-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2185381C2 (en) | Amide derivative and pharmaceutical composition | |
| JP2756742B2 (en) | N-acyl-2,3-benzodiazepine derivatives, method for producing the same, pharmaceutical compositions containing the same, and methods for producing the same | |
| KR100667645B1 (en) | Cyclic amine ccr3 antagonists | |
| KR101991327B1 (en) | Opioid Receptor Ligands and Methods of Using and Making Same | |
| DE60029235T2 (en) | FAB I INHIBITORS | |
| DE4326465A1 (en) | Amino acid derivatives, pharmaceutical compositions containing these compounds and process for their preparation | |
| JP2008513508A (en) | Compounds used for inflammation and immunity related applications | |
| JP5042987B2 (en) | Trifluoromethylbenzamide derivatives and their therapeutic use | |
| JPH08502511A (en) | Uses as 4-carboxamide piperidine derivatives, intermediates and neurokinin antagonists | |
| HUT75876A (en) | Amidine derivatives with nitric oxide synthetase activities, pharmaceutical compositions containing them and process for their preparation | |
| JP2011157387A (en) | Substituted 2-aminoacetamide and use thereof | |
| MX2007003836A (en) | Substituted 2h-1,3-benzoxazin-4(3h)-ones. | |
| DE4219158A1 (en) | Biphenyl derivatives, pharmaceutical compositions containing them and processes for their preparation | |
| JP3498849B2 (en) | Bicyclic heterocyclic compounds as neurokinin A antagonists | |
| KR100759744B1 (en) | Arylene-carboxylic acid2-amino-phenyl-amide derivatives as pharmaceutical agents | |
| EP1224163B1 (en) | Use of carbonylamino derivatives against cns disorders | |
| US4868175A (en) | 4-Benzyl-1-(2H)-phthalazineone derivatives having an amino acid radical | |
| EP0648489A1 (en) | Arylalkylamides having neuroprotective properties | |
| JP2580196B2 (en) | Amino acid derivative antispasmodic | |
| US5859033A (en) | Anticonvulsant pyridinyl benzamide derivatives | |
| AU710071B2 (en) | Anticonvulsant pyridinyl benzamide derivatives | |
| US3966938A (en) | Treatment of thrombosis and the inhibition of blood platelet aggregation | |
| EP0278090B1 (en) | 2-Aminoacetamide pyridinyl derivatives | |
| JPH0530828B2 (en) | ||
| US5658923A (en) | Azepine derivatives and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |